Amicus Therapeutics, Inc.  

(Public, NASDAQ:FOLD)   Watch this stock  
Find more results for FOLD
-0.08 (-1.18%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.45 - 6.78
52 week 4.98 - 18.83
Open 6.78
Vol / Avg. 2.13M/2.50M
Mkt cap 814.26M
P/E     -
Div/yield     -
EPS -1.28
Shares 127.05M
Beta 1.77
Inst. own 113%
Aug 3, 2016
Q2 2016 Amicus Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 9, 2016
Amicus Therapeutics Inc Annual Shareholders Meeting
Jun 9, 2016
Amicus Therapeutics Inc Annual Shareholders Meeting (Estimated)
Jun 7, 2016
Amicus Therapeutics Inc at Goldman Sachs Global Healthcare Conference - Webcast
May 11, 2016
Amicus Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference
May 3, 2016
Q1 2016 Amicus Therapeutics Inc Earnings Release
May 3, 2016
Q1 2016 Amicus Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -19.79% -23.63%
Return on average equity -53.15% -56.22%
Employees 185 -
CDP Score - -


1 Cedarbrook Dr
CRANBURY, NJ 08512-3618
United States - Map
+1-609-6622000 (Phone)
+1-609-6622001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.

Officers and directors

John F. Crowley J.D. Chairman of the Board, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Bradley L. Campbell President, Chief Operating Officer
Age: 39
Bio & Compensation  - Reuters
William D. Baird III Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
Kurt J Andrews Senior Vice President - Human Resources
Age: 45
Bio & Compensation  - Reuters
David Allsop Senior Vice President - International
Bio & Compensation  - Reuters
Dipal Doshi Senior Vice President - Business Planning and Development
Age: 39
Bio & Compensation  - Reuters
Ken Valenzano Ph.D. Senior Vice President - Preclinical Research
Age: 47
Bio & Compensation  - Reuters
Hung Viet Do Chief Scientific Officer
Age: 47
Bio & Compensation  - Reuters
Enrique Dilone Ph.D. Vice President - Technical Operations
Age: 48
Bio & Compensation  - Reuters
Daphne E. Quimi Vice President - Finance, Controller
Age: 49
Bio & Compensation  - Reuters